3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Brain Neoplasms
4
Neoplasms
3
Glioma
3
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoproliferative Disorders
2
Hematologic Neoplasms
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Solid Tumors
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasms, Unknown Primary
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Interventions
Gemcitabine
33
Cisplatin
28
pembrolizumab
19
durvalumab
17
Oxaliplatin
16
Fluorouracil
16
Leucovorin
14
Magnetic Resonance Spectroscopy
13
Specimen Handling
9
Biopsy
9
lenvatinib
7
Nivolumab
7
Capecitabine
7
Taxes
6
Paclitaxel
6
Irinotecan
6
fludarabine
5
Folfox protocol
5
Drug Therapy
5
Carboplatin
5
Albumin-Bound Paclitaxel
5
pemigatinib
4
Ipilimumab
4
Fluorodeoxyglucose F18
4
Floxuridine
4
Cyclophosphamide
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
tremelimumab
3
olaparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
entrectinib
×
1 year
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA